ClinicalTrials.gg
Not yet recruitingNCT07738341Updated Jul 31, 2026

GB268 Monotherapy or Combination Therapy for Locally Advanced/Metastatic Breast Cancer (Phase Ib/Ⅱ)

A Phase 1/2 interventional study of GB268 and Nab-Paclitaxel in Breast Cancer (Locally Advanced or Metastatic), sponsored by Eddingpharm (Zhuhai) Co., Ltd.. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-31.

Sponsored by Eddingpharm (Zhuhai) Co., Ltd. · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
270
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a Phase Ib/II, open-label, multi-cohort, multi-center study to evaluate the safety, tolerability, and preliminary anti-tumor activity of GB268, a biological product, as monotherapy or in combination with other therapies in patients with locally advanced unresectable or metastatic breast cancer.

Read the detailed description

The Phase Ib part of the study will primarily assess the safety and tolerability of GB268 in combination therapies, including dose-limiting toxicities (DLTs). The Phase II part will primarily evaluate the preliminary anti-tumor activity of GB268 as monotherapy and in various combination regimens in corresponding breast cancer populations.

02

Conditions studied

  • Breast Cancer (Locally Advanced or Metastatic)

Keywords

  • GB268
  • Immunotherapy
  • PD-1
  • CTLA-4
  • VEGF
03

In context

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

This study's planned enrollment of 270 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.

Browse Breast Neoplasms studies →

Lead sponsor

Eddingpharm (Zhuhai) Co., Ltd. is the lead sponsor of 4 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Cohort-Specific Requirements:

Cohort A: confirmed locally advanced unresectable or Triple-Negative Breast Cancer [TNBC]; no prior systemic therapy for advanced disease; prior adjuvant/ taxane allowed if recurrence ≥6 months after last taxane dose; no prior Trop-2 Antibody-Drug Conjugate [ADC].

Cohort B: Histologically confirmed locally advanced unresectable or metastatic TNBC; no prior systemic therapy for advanced disease; prior adjuvant/neoadjuvant taxane allowed if recurrence ≥12 months after last taxane dose.

Cohort E: Histologically confirmed locally advanced unresectable or metastatic HR+/- breast cancer; disease progression after ≥1 line of endocrine therapy (aromatase inhibitor and/or fulvestrant) and CDK4/6i in advanced setting; received ≥1 in advanced setting; no prior Trop-2 ADC.

Cohort F: Histologically confirmed locally advanced unresectable or metastatic HR+/HER2- breast cancer; disease progression after ≥1 line of endocrine therapy and CDK4/6i with primary or secondary endocrine resistance; prior adjuvant/neoadjuvant taxane allowed if recurrence ≥12 months after last taxane dose.

Cohort G: Histologically confirmed locally advanced unresectable or metastatic HR+/HER2- breast cancer; prior CDK4/6i and endocrine therapy in any setting; received a TROP2 or HER2 ADC in advanced setting.

Inclusion criteria

Inclusion Criteria:

  1. Age ≥ 18 years, male or female.
  2. Histologically confirmed locally advanced unresectable or metastatic breast cancer (Triple-Negative Breast Cancer [TNBC] or Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative [HR+/HER2-]).
  3. At least one per version 1.1 [RECIST v1.1].
  4. No prior treatment with any (e.g., anti-Programmed Death-1 [PD-1], anti-Programmed Death-Ligand 1 [PD-L1], anti-Cytotoxic T-Lymphocyte-Associated Protein 4 [CTLA-4]) or Programmed Death-1/Vascular Endothelial Growth Factor [PD-1/VEGF] bispecific antibody, except for adjuvant therapy if relapse occurred ≥12 months after discontinuation.
  5. Assessed by the investigator as suitable for the assigned combination therapy.
  6. [ECOG] performance status 0 or 1.
  7. ≥ 3 months.
  8. Adequate organ function (within 14 days before first dose, without transfusion or Granulocyte Colony-Stimulating Factor [G-CSF] support): ≥ 9 g/dL, [ANC] ≥ 1.5×10\^9/L, ≥ 100×10\^9/L; [AST] and Alanine Aminotransferase [ALT] ≤ 3× [ULN] (≤5×ULN if liver metastases); Alkaline Phosphatase [ALP] ≤ 2.5×ULN (≤5×ULN if bone or liver metastases); Total ≤ 1.5×ULN (≤3×ULN for Gilbert's Syndrome); Serum Creatinine ≤ 1.5×ULN or ≥ 50 mL/min (Cockcroft-Gault formula); Urine protein dipstick ≤ 1+ (if ≥2+, 24-hour urine protein quantification \< 1 g); Coagulation function: [INR] or activated Partial Thromboplastin Time [aPTT] ≤ 1.5×ULN (for patients not on anticoagulation therapy).
  9. Provide a Formalin-Fixed Paraffin-Embedded [FFPE] tumor tissue sample for biomarker testing.
  10. Effective for fertile participants.

Exclusion criteria

Exclusion Criteria:

  1. Prior anti-cancer therapy within specified .
  2. Systemic therapy within 2 weeks before first dose.
  3. Major surgery or significant traumatic injury within 4 weeks before first dose.
  4. Unresolved toxicity from prior therapy > Grade 1 (except alopecia or Grade ≤2 hypothyroidism stable on hormone replacement).
  5. Prior immune-related adverse events [irAEs] ≥ Grade 3 leading to treatment discontinuation.
  6. Active Central Nervous System [CNS] (except stable asymptomatic lesions).
  7. History of other within 3 years (except cured non-melanoma skin cancer or carcinoma in situ).
  8. Uncontrolled pleural effusion or ascites requiring repeated drainage.
  9. cardiovascular disease (e.g., myocardial infarction, unstable angina, stroke within 6 months; prolongation; [NYHA] Class II-IV heart failure; pericarditis/myocarditis).
  10. History of Interstitial Lung Disease [ILD] or non-infectious pneumonitis requiring .
  11. Active or history of disease requiring systemic treatment in the past 2 years.
  12. History of inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis, or chronic diarrhea).
  13. History of hypertensive crisis or hypertensive encephalopathy.
  14. Severe coagulation disorders or significant bleeding risk (e.g., severe vascular disease, hemoptysis, intracranial/spinal hemorrhage, tumor invading major vessels).
  15. History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess.
  16. Active infection requiring systemic anti-infective therapy within 2 weeks; severe infection within 4 weeks.
  17. Uncontrolled intercurrent illness (e.g., poorly controlled hypertension or Type 2 diabetes mellitus).
  18. Known active tuberculosis [TB].
  19. Positive for Virus [HBV] surface antigen [HBsAg] or core antibody [HBcAb] with HBV-Deoxyribonucleic Acid [DNA] > 500 IU/mL; or positive Virus [HCV] antibody with HCV-Ribonucleic Acid [RNA] above the lower limit of quantification.
  20. Known primary immunodeficiency or positive [HIV] antibody.
  21. History of solid organ or hematopoietic stem cell transplantation (except corneal transplant).
  22. Pregnant or breastfeeding women.
  23. Known to GB268 or its ; history of severe hypersensitivity to other monoclonal antibodies.
  24. Any other condition that would make the participant unsuitable for the study.
  25. History of severe hypersensitivity to other drugs in the combination regimen.
Terms in these criteria, in plain language(32)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
270 participants (estimated)

Study arms

  • Experimental
    Cohort A (GB268 + Sacituzumab Tirumotecan)

    GB268 (10 or 20 mg/kg Q3W intravenously \[IV\], dose selected by Safety Review Committee \[SRC\]) + Sacituzumab Tirumotecan 5 mg/kg once every 2 weeks \[Q2W\] IV. For participants with locally advanced/metastatic Triple-Negative Breast Cancer \[TNBC\] with no prior systemic therapy for advanced disease; no prior Trop-2 Antibody-Drug Conjugate \[ADC\].

    Drug: GB268 · Drug: Sacituzumab Tirumotecan

  • Experimental
    Cohort B (GB268 + Nab-Paclitaxel)

    GB268 (10 or 20 mg/kg Q3W IV) + Nab-Paclitaxel 260 mg/m² Day 1 Q3W IV. For participants with locally advanced/metastatic TNBC with no prior systemic therapy for advanced disease; prior adjuvant/neoadjuvant taxane allowed only if recurrence ≥12 months after last taxane dose.

    Drug: GB268 · Drug: Nab-Paclitaxel

  • Experimental
    Cohort E (GB268+ Datopotamab Deruxtecan)

    GB268 (10 or 20 mg/kg Q3W IV) + Datopotamab Deruxtecan 6 mg/kg Day 1 Q3W IV. For participants with HR+/HER2- breast cancer who have received at least 1 line of endocrine therapy, CDK4/6i, and at least 1 line of systemic chemotherapy in the advanced setting; no prior Trop-2 ADC.

    Drug: GB268 · Drug: Datopotamab Deruxtecan (Dato-DXd)

  • Experimental
    Cohort F (GB268 + Nab-Paclitaxel)

    GB268 (10 or 20 mg/kg Q3W IV) + Nab-Paclitaxel 260 mg/m² Day 1 Q3W IV. For participants with HR+/HER2- breast cancer with disease progression after ≥1 line of endocrine therapy and CDK4/6i, with primary or secondary endocrine resistance; prior adjuvant/neoadjuvant taxane allowed only if recurrence ≥12 months after last taxane dose.

    Drug: GB268 · Drug: Nab-Paclitaxel

  • Experimental
    Cohort G (GB268 monotherapy)

    GB268 monotherapy (dose not exceeding 30 mg/kg Q3W, selected by SRC) IV. For participants with HR+/HER2- breast cancer who have received prior CDK4/6i and endocrine therapy in any setting, and a TROP2 or HER2 ADC in the advanced setting.

    Drug: GB268

Interventions

  • DrugGB268

    GB268 is a tri-specific antibody targeting PD-1, CTLA-4, and VEGF. It is designed to block immune checkpoints (PD-1/CTLA-4) to enhance T-cell-mediated anti-tumor immune responses and simultaneously inhibit VEGF-mediated tumor angiogenesis

  • Nab-Paclitaxel is a microtubule-stabilizing agent formulated as albumin-bound nanoparticles for IV administration.

  • Datopotamab Deruxtecan is an ADC targeting Trop-2, consisting of a monoclonal antibody linked to a topoisomerase I inhibitor payload.

  • A Trop-2-directed Antibody-Drug Conjugate \[ADC\] consisting of a humanized anti-Trop-2 monoclonal antibody covalently linked to a topoisomerase I inhibitor payload.

06

What researchers measure

Primary outcomes

  1. Dose-Limiting Toxicities [DLTs] (Phase Ib)

    Incidence of Dose-Limiting Toxicities \[DLTs\] during the first treatment cycle

    Time frame: Within 21 days after first dose

  2. Objective Response Rate [ORR] (Phase II)

    ORR is the proportion of subjects with complete response(CR) or partial response(PR) , based on Investigator per Response Evaluation Criteria in Solid Tumors version 1.1 \[RECIST v1.1\]

    Time frame: Up to approximately 2 years

Secondary outcomes

  1. Number of participants with adverse events [AEs] (Phase Ib and Phase II)

    Safety as assessed by clinical laboratory tests, 12-lead electrocardiogram (ECG), vital signs measurements, and the incidence, nature and severity of all adverse events (AEs) and serious AEs (SAEs)

    Time frame: Up to approximately 2 years

  2. Objective Response Rate [ORR] (Phase Ib)

    ORR is the proportion of subjects with complete response(CR) or partial response(PR) , based on RECIST v1.1.

    Time frame: Up to approximately 2 years

  3. Duration of Response [DOR] (Phase Ib and Phase II)

    DOR assessed according to RECIST v1.1

    Time frame: Up to approximately 2 years

  4. Overall Survival [OS] (Phase Ib and Phase II)

    OS defined as the time from the first dose to death from any cause

    Time frame: Up to approximately 2 years

  5. Disease Control Rate [DCR] (Phase Ib and Phase II)

    DCR assessed according to RECIST v1.1

    Time frame: Up to approximately 2 years

  6. Progression-Free Survival [PFS] (Phase Ib and Phase II)

    PFS assessed according to RECIST v1.1

    Time frame: Up to approximately 2 years

  7. Cmax of GB268 of GB268 (Phase Ib and Phase II)

    Peak plasma concentration

    Time frame: Up to approximately 2 years

  8. Tmax of GB268 (Phase Ib and Phase II)

    Time to peak drug concentration

    Time frame: Up to approximately 2 years

  9. AUC of GB268 (Phase Ib and Phase II)

    Area under curve

    Time frame: Up to approximately 2 years

  10. Number and percentage of participants with Anti-Drug Antibodies [ADAs] (Phase Ib and Phase II)

    Time frame: Up to approximately 2 years

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2026; primary completion for Aug 2029, 36 months later.

Of 161 industry-sponsored phase 1/2 interventional studies under Breast Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 75. This study's planned 36 months is below that.

Counting every sponsor, half of 328 studies reached it within 61 months; a quarter within 45 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 23, 2026
First posted
Jul 31, 2026
StartEst.
Aug 1, 2026
Primary completionEst.
Aug 1, 2029
CompletionEst.
Aug 1, 2030
Last update
Jul 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07738341
Lead sponsor
Eddingpharm (Zhuhai) Co., Ltd.
Responsible party
Sponsor
First posted
Jul 31, 2026
Start date
Aug 1, 2026 (estimated)
Primary completion
Aug 1, 2029 (estimated)
Completion
Aug 1, 2030 (estimated)
Last update
Jul 31, 2026

Study contacts

Binghe Xu
Contact
xubinghe@medmail.com.cn
86 10 67781331

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion